Cross-cultural Adaptation of the Safety Assessment Scale for Elderly People With a Major Neurocognitive Disorder Living at Home.

NCT ID: NCT05485090

Last Updated: 2025-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

116 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-01

Study Completion Date

2023-12-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to adapt the Canadian French version of the safety assessment scale for use in France. The Safety Assessment Scale was developped for community healthcare providers working with elderly people with dementia who are being cared for at home, to assess the risk of accidents. The short version of the Safety Assessment Scale is a screening tool and the longer version provides an in-depth evaluation of safety.

This scale is a risk assessment grid for accidents and injuries at home for elderly people with major neurocognitive disorders, available in English and French (Canadian). There are two versions:

* The short version is used for screening. A score of 11 to 14 indicates a moderate risk of injury, while a score ≥ 15 indicates a high risk of injury;
* The long version is used for in-depth assessment when the score on the short version indicates a moderate or high risk of injury. The questionnaire is divided into nine sections:

1. Caregiver and environment, 2/smoking, 3/fire and burns, 4/nutrition, 5/food poisoning and toxic substances, 6/medication and health problems, 7/wandering and adaptation to temperature changes, 8/trauma, and 9/driving.

The short version includes some of the questions from sections 1 to 7 of the long version.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Secondary objectives:

The other objectives of this study are to assess the test-retest reliability and the inter-rater reliability of the translated scale and to evaluate the internal consistency of the long version of the translated scale.

Conduct of research:

Caregivers of patients with major neurocognitive disorders included in the study will complete the adapted scale with an investigator. A pre-test phase will be carried out with 10 caregivers: the caregivers will complete the questionnaire only once with an investigator.

After this phase, the translated Safety Assessment Scale will be corrected if there are difficulties in understanding certain words or sentences. The new scale will then be evaluated on two cohorts of 53 caregivers (cohort 1: caregivers will complete the adapted scale twice with the same investigator; cohorte 2: caregivers will complete the adapted scale twice with two different investigators).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Neurocognitive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Phase : Test-Retest Reliability

Caregivers will complete the questionnaire twice with the same investigator. The interval between the two questionnaires is 3 to 10 days.

Questionnaire : Adapted Safety Assessment Scale

Intervention Type OTHER

Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.

Test Phase : Inter-rater Reliability

Caregivers will complete the questionnaire twice with two different investigators. The interval between the two questionnaires is 3 to 10 days.

Questionnaire : Adapted Safety Assessment Scale

Intervention Type OTHER

Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire : Adapted Safety Assessment Scale

Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient living at home or hospitalized with a planned return home
* Patient with a major neurocognitive disorder (Diagnostic and Statistical Manual of Mental Disorders, fifth version) :

* evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, social cognition) based on : a concern by the individual, a knowledgeable informant, or the clinician about a significant decline in cognitive function ; and a deficit in cognitive performance, preferably documented by standardized neuropsychological tests or by another quantified clinical assessment
* the cognitive deficits interfere with independence in daily activities. At least, assistance should be required with complex instrumental activities of daily living, such as paying bills or managing medications.
* the cognitive deficits do not occur exclusively in the context of a delirium.
* the cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia).
* Patient with at least one caregiver:

* reliable (no suspicion of cognitive or psychiatric disorders and/or inappropriate behavior such as manipulation or abuse)
* able to answer the questionnaire (i.e., knows the patient's lifestyle)
* No objection to participating in the study from the caregiver and the patient (if able to understand the study)
* No objection to guardian participation for patients under guardianship or curatorship

Exclusion Criteria

* Patient totally socially isolated or without a reliable caregiver
* Bedridden patients
* For hospitalized patients, no planned return home
* Patients under judicial protection
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clémence BONNOT, Occupational Therapist

Role: PRINCIPAL_INVESTIGATOR

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GHRMSA

Mulhouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A02428-33

Identifier Type: OTHER

Identifier Source: secondary_id

GHRMSA 1209

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Memory and Social Interactions
NCT05800028 RECRUITING